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Available online 30 July 2007AbstractThe clinical significance of serum cathepsin K and cystatin C was assessed in patients with breast cancer (BCa) or prostate cancer (PCa) with
confined disease (M0) or bone metastasis (BM). Cathepsin K and cystatin C circulating levels were determined by ELISAs in 63 cancer patients,
in 35 patients with nonmalignant diseases and in 42 healthy blood donors (control group). In BCa patients, cathepsin K serum levels were sig-
nificantly lower than in sex matched control group (HS; p¼ 0.0008) or in patients with primary osteoporosis (OP; p¼ 0.0009). On the contrary,
cystatin C levels were significantly higher in BCa patients than in HS ( p¼ 0.0001) or OP ( p¼ 0.017). In PCa patients, cathepsin K concen-
trations did not significantly differ from those measured in sex matched HS or in patients with benign prostatic hyperplasia (BPH). Conversely,
cystatin C was more elevated in cancer patients than in controls ( p¼ 0.0001) or BPH patients ( p¼ 0.0078). Furthermore, in PCa patients, a pos-
itive correlation was observed between cystatin C and cathepsin K (rS¼ 0.34; p¼ 0.047). No further relationship was highlighted between these
molecules and the clinicobiological parameters of BCa or PCa progression including the number of bone lesions. Moreover, ROC curve analysis
showed a poor diagnostic performance of cathepsin K and cystatin C in the detection of BM patients. Interestingly, the administration of zole-
dronic acid (ZA), a bisphosphonate derivative endowed with a potent antiosteoclastic activity, induced in BM patients a marked increase of
cathepsin K and cystatin C serum levels compared to baseline values. However, this phenomenon was statistically significant only in the
PCa group. In conclusion Cystatin C and cathepsin K may be regarded as possible markers to monitor the therapeutic response to bisphosphonate
treatments. Nevertheless, their clinical value as specific gauges of skeletal metastasis remains questionable.
 2007 Elsevier Masson SAS. All rights reserved.
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Cathepsin K (Cath K) is a member of the cysteine protein-
ase family predominantly expressed in osteoclasts [1,2].Abbreviations:AUC, area under the curve; BCa, breast cancer; BM, boneme-
tastasis; BPH, benign prostatic hypertrophy; CathK, cathepsin K; CA15.3, carbo-
hydrate antigen 15.3; Cyst C, cystatin C; ELISA, enzyme-linked immunosorbent
assay;HS, healthy subjects;M0, localized disease;OP, primaryosteoporosis; PCa,
prostate cancer;PSA, prostate specificantigen;ROC, receiveroperating character-
istic curve; TGF-b, transforming growth factor-beta; ZA, zoledronic acid.
* This work was supported by funds from Ministero della Universita` e della
Ricerca (MiUR ex 60%).
* Corresponding author. Tel.: þ39 091655 2048; fax: þ39 091655 2760.
E-mail address: gleto@unipa.it (G. Leto).
0753-3322/$ - see front matter  2007 Elsevier Masson SAS. All rights reserved.
doi:10.1016/j.biopha.2007.07.001However, recent observations report its presence also in oste-
oblasts [3]. Current studies indicate that this proteinase
appears to play a key role in osteoclast-mediated bone
resorption as, unlike other cathepsins, it has been shown to de-
grade specifically bone resident type I collagen which consti-
tutes 90% of the organic bone matrix [1,2]. The intracellular
activity of Cath K is regulated by specific endogenous cysteine
proteinase inhibitors such as cystatin C (Cyst C) [4,5]. Inter-
estingly, recent findings highlight that this inhibitor, besides
its enzyme inhibiting activity, may also decrease osteoclast
formation and antagonize transforming growth factor-beta
(TGF-b) signalling in normal and tumor cells [4,6,7]. These
observations suggest that Cyst C may be implicated in the
modulation of osteoclast and osteoblast activity during bone
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the expression level of Cath K and/or Cyst C may result in
disturbances of the normal metabolic turnover of bone tissue,
which may lead to the onset of severe bone diseases. This
hypothesis is corroborated by several clinical studies which
highlighted that the expression levels of Cath K and/or Cyst
C are altered in a number of nonmalignant and malignant
diseases associated with an excessive bone resorption such
as muscoloskeletal disorders, primary bone tumors or bone
metastasis [4,8e18]. These findings suggest that Cath K and
Cyst C may be regarded as suitable targets for appropriate
treatments of these pathological processes and may be of value
as additional circulating markers for the therapeutic monitor-
ing and follow-up of patients with these diseases [4,9]. On
the basis of these considerations we have undertaken some in-
vestigations to assess the role and the clinical significance of
the circulating levels of Cath K and Cyst C in patients with
bone metastasis from breast cancer (BCa) or prostate cancer
(PCa). These tumors were chosen as (i) they metastasize pref-
erentially to the bone and (ii) may induce different types of
bone lesions, namely, lytic (breast cancer) or blastic (prostate
cancer) [19]. Finally, in order to assess the role of these mol-
ecules as additional markers for the therapeutic monitoring of
BM patients undergoing palliative treatments with bisphosph-
onates, parallel studies were undertaken to evaluate the effects
of zoledronic acid (ZA), a third generation bisphosphonate
derivative endowed with a potent antiosteoclastic activity,
[20] on the circulating levels of Cath K and Cyst C.
2. Patients and methods
The study included 42 registered healthy blood donors (HS)
of both sexes (21 female and 21 male) who served as a control
group, 15 female patients with age-related osteoporosis (OP;
mean age 74.1 10.5 years), 20 patients with histologically
confirmed benign prostatic hyperplasia (BPH; mean age
62.4 6.3 years), 28 patients with breast cancer (BCa; mean
age 59.3 9.8 years) and 35 patients with prostate cancer
(PCa; mean age 72.1 8.3 years). Both BCa and PCa groups
comprised patients with localized disease (M0) and patients
with bone metastases (BM) and no clinical evidence of extra-
skeletal involvement. BM patients underwent serial treatments
with the bisphosphonate derivative zoledronic acid (ZA)
(Zometa Novartis, Basel, Switzerland, 4 mg i.v. by a 15-min
infusion every 21 days) as described in detail elsewhere
[21]. The study was approved by the local ethical committee
and carried out in accordance with the Declaration of
Helsinki [22].2.1. Cathepsin K and Cystatin C assayBlood specimens from cancer patients, OP patients or BPH
patients were obtained before starting any therapy. An addi-
tional blood sample was obtained from patients treated with
ZA, prior to the second drug administration (day 21). Samples
were drawn into polycarbonate tubes, allowed to clot at room
temperature and then centrifuged at 3500 rpm for 15 min(Hereus Omnifuge 2.0 RS, Hereus Sepatech). Serum aliquots
were stored at 80 C until assays. Cath K and Cyst C serum
concentrations were determined by commercially available
two-step sandwich enzyme-linked immunosorbent assay
(ELISA) kits according to the manufacturers’ instruction (Ca-
thepsin K ELISA kit Biomedica, Wien, Austria; Cystatin C
(human) ELISA kit, Biovendor, Modrice, Czech Republic).
The detection limits reported by the manufacturers were
1.1 pmol/L for cathepsin K and 80 mg/L for cystatin C.2.2. Statistical analysisStatistical analysis was carried out, where required, by the
nonparametric ManneWhitney U test, the Wilcoxon signed
rank test and the KruskaleWallis test. Linear regression anal-
ysis was used to assess the correlation between circulating
Cath K and Cyst C in BCa and PCa patients. The diagnostic
sensitivity and the specificity of Cath K and Cyst C to discrim-
inate between M0 and BM patients were determined by the
receiver operating characteristic curve (ROC) [23]. The signif-
icance of the difference between the areas under the ROC
curves (AUCs) was assessed according to Hanley and McNeil
[24]. p-Values 0.05 were considered statistically significant.
Data analysis was performed by using the Medcalc 7.4 statis-
tical software package (MEDCALC version 7.4, Mariakerke,
Belgium).
3. Results
Cath K serum levels were significantly higher in HS (mean
11.3 14.0 pmol/L) or OP patients (mean 3.7 2.9 pmol/L)
than in BCa patients (mean 1.2 1.9 pmol/L) (Fig. 1 and
Table 1). Conversely, Cyst C levels were significantly higher
in BCa patients (mean 1.5 0.59 mg/L) than in sex matched
HS (mean 0.85 0.16 mg/L) or OP patients (mean
1.1 0.24 mg/L) (Fig. 1 and Table 1). However, in cancer
patients no significant association was observed between
serum Cath K and Cyst C, nor Cath K or Cyst C levels were
correlated with any of the clinicobiological parameters of
BCa progression considered in the present study, namely,
tumor grade (Cath K, p¼ 0.70; Cyst C, p¼ 0.24), estrogen
receptors (Cath K, p¼ 0.54; Cyst C, p¼ 0.50), progesterone
receptors (Cath K, p¼ 0.92; Cyst C, p¼ 0.66), serum
CA15.3 (Cath K, p¼ 0.82; Cyst C, p¼ 0.18) and number of
bone lesions (Cath K, p¼ 0.088; Cyst C, p¼ 0.5). In PCa
patients, Cath K levels (mean 20.7 50.5 pmol/L) did not sig-
nificantly differ from those measured in sex matched HS (mean
9.6 20.7 pmol/L) or in BPH patients (mean 1.6 2.3 pmol/L)
(Fig. 1 and Table 1). Furthermore, no relationship was high-
lighted between this proteinase and some clinicobiological
parameters of progression, such as Gleason score ( p¼ 0.4),
number of skeletalmetastases ( p¼ 0.44) or prostate specific an-
tigen (PSA) levels ( p¼ 0.32) while a positive correlation was
highlighted between Cyst C and Cath K (Fig. 2) . On the other
hand, the circulating levels of Cyst C were significantly in-
creased in PCa patients (mean 1.7 0.65 mg/L) as compared
to HS (mean 1.1 0.24 mg/L) or BPH patients (mean
Table 1
Statistical evaluation of the data reported in Fig. 1
p-Valuea
Cathepsin K Cystatin C
Breast cancer groupb
HS vs OP 0.28 n.s. 0.0021
HS vs M0 0.0021 <0.0001
HS vs BM 0.016 0.0001
OP vs M0 0.0013 0.033
OP vs BM 0.017 0.044
M0 vs BM 0.94 n.s. 0.82 n.s.
Prostate cancer groupb
HS vs BPH 0.085 n.s. 0.41 n.s.
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Fig. 1. Cathepsin K and cystatin C serum levels in healthy subjects (HS), in patients with primary osteoporosis (OP) or benign prostate hyperplasia (BPH) and in
breast cancer or prostate cancer patients with (BM) or without (M0) bone metastases.
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concentrations of this inhibitor did not correlate with the Glea-
son score ( p¼ 0.88), PSA serum levels ( p¼ 0.26) or the num-
ber of bone lesions ( p¼ 0.34) in this case too (Fig. 1 and Table
1). Furthermore, ROC curve analysis generated to assess the ef-
fectiveness of serumCath K and Cyst C to discriminate between
M0 and BM patients, showed a poor diagnostic performance of
thesemolecules in this respect (Fig. 3 andTable 2). Interestingly,
the administration of ZA to patients with bone metastasis in-
duced a marked increase of cathepsin K and cystatin C serum
levels compared to pre-treatment serum levels (Fig. 4). How-
ever, statistically significant differences between pre- and
post-treatment values were noted only in PCa patients (Cath
K, p¼ 0.018; Cyst C, p¼ 0.0001) (Fig. 4).HS vs M0 0.62 n.s. 0.01
HS vs BM 0.2 n.s. 0.0001
BPH vs M0 0.33 n.s. 0.13 n.s.
BPH vs BM 0.92 n.s. 0.0032
M0 vs BM 0.97 n.s. 0.15 n.s.
a Data analysis was computed by the non parametric ManneWhitney U test;
n.s.¼ not significant.
b HS¼ healthy subjects; OP¼ primary osteoporosis; BPH¼ benign pros-
tatic hyperplasia; M0¼ primary tumor; BM¼ bone metastasis.4. Discussion
Cathepsin K and Cystatin C are highly expressed in a num-
ber of malignant diseases associated with an altered metabolic
turnover of bone tissue [4,11,15e18,25e27]. These observa-
tions are suggestive for an active involvement of the cathepsin
Fig. 2. Linear regression analysis between cathepsin K and cystatin C serum levels in patients with breast cancer or prostate cancer.
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bone disease. Therefore, the role and the clinical significance
of the circulating levels of these molecules were investigated
in patients with bone metastasis from breast cancer or prostate
cancer. Furthermore, because zoledronic acid, a bisphospho-
nate derivative used in the palliative treatment of bone metas-
tasis [20], strongly inhibits osteoclast activity, parallel studies
were carried out to assess the effect of this drug on the serum
levels of cathepsin K and cystatin C. These investigations
show that cystatin C is significantly increased in cancer pa-
tients as compared to healthy subjects or to patients with non-
malignant diseases. The increased levels of this inhibitor in
cancer patients does not seem to be due to an impaired kidney
function as none of these patients showed clinically evident al-
teration in renal function. Therefore, these data are consistent
with those from other studies reporting that cystatin C levels
are enhanced in malignant tissues or in body fluids of patients
with neoplastic diseases including patients with breast cancer
or prostate cancer and that this phenomenon is associated with
more aggressive forms of these tumors [4,11,26e30]. TheseFig. 3. ROC curves for cathepsin K and cystatin C in patients with brfindings support the concept that cystatin C may facilitate
the malignant progression of these tumors [4,26,27,30]. On
the other hand, recent experimental evidence showing that
this inhibitor may directly promote tumor cell proliferation
and dissemination by other mechanisms not related to its en-
zyme inhibiting activity, further corroborates this hypothesis
[4,7,26,31,32]. Therefore, cystatin C may be regarded as
a novel target for cancer therapy and as a possible marker of
cancer progression [4,30]. However, its clinical value as spe-
cific gauge of metastatic bone disease remains controversial.
In fact, the lack of significant differences in the serum concen-
trations of cystatin C between M0 and BM patients either in
BCa or in PCa and the poor diagnostic accuracy of this inhib-
itor to detect BM patients, seems to rule out a direct involve-
ment of this molecule in bone metastasis formation and its
usefulness as specific marker of metastatic spread to the
bone. Surprisingly, the present data show that cathepsin K
blood levels are markedly lower (mean 9.4-fold) in BCa pa-
tients than in HS or in OP patients (mean 3.1-fold), while in
PCa patients the serum concentrations of this proteinase areeast cancer or prostate cancer with and without bone metastases.
Table 2
Sensitivity, specificity and diagnostic accuracy of cathepsin K and cystatin C in the detection of patients with bone metastases
AUC (95% C.I.) Cut-off valuesa Sensitivity (95% C.I.) Specificity (95% C.I.) Accuracy (%)
Breast cancer
Cathepsin K 0.49 0.12 (0.30e0.67) p¼ 0.94 n.s. 4.9 pmol/L 11.1 (1.8e48.3) 100 (82.2e100) 67.8
Cystatin C 0.47 0.11(0.29e0.67) p¼ 0.82 n.s. 1.41 mg/L 90 (55.5e98.3) 42.1 (20.3e66.6) 39.3
Prostate cancer
Cathepsin K 0.56 0.10 (0.38e0.72) p¼ 0.96 n.s. 3.7 pmol/L 78.9 (54.4e93.8) 43.7(19.8e70.1) 45.7
Cystatin C 0.64 0.13(0.46e0.79) p¼ 0.13 n.s. 1.36 mg/L 90.0 (55.5e98.3) 37.5(15.3e64.5) 65.7
AUC¼ area under the curve.
a Cut-off values were determined by ROC curve analysis.
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patients. Furthermore, no significant difference in the serum
content of this enzyme was observed between M0 and BM pa-
tients. These results seem to question an involvement of ca-
thepsin K in bone metastasis formation. On the other hand,
recent experimental observations by Garnero et al. [33] indi-
cate that this proteinase appears to be mainly implicated in
the degradation of collagen in osteoporosis, while matrix met-
alloproteinases seem to play a major role in the degradation of
bone collagen in metastatic bone disease. These findings may
fit well with the results showing significantly higher circulat-
ing levels of cathepsin K (mean 2.5-fold) in OP patients
than in BM patients. However, it cannot be ruled out that
this proteinase, which has its optimum activity in an acid mi-
croenvironment as encountered in the resorption lacunae, may
act locally and for this reason may not be secreted in excess
into the extracellular space or into the bloodstream [1,2,34].
Although these observations do not rule out a direct involve-
ment of cathepsin K in bone metastasis formation, they sug-
gest that this proteinase does not appear suitable as
additional serum marker of metastatic spread to the bone.Cathepsin K
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Fig. 4. Effects of zoledronic acid administration (4 mg i.v.) on cathepsin K and cyst
prostate cancer.Interestingly, our results show that the administration of ZA
induces a statistically significant increase of serum cathepsin
K and cystatin C only in patients with bone metastasis from
prostate cancer, a tumor which is known to induce mainly os-
teoblastic or mixed osteolytic/osteoblastic metastasis [19]. As
recent studies show that this proteinase is secreted also by os-
teoblasts [3] and that cystatin C appears to modulate osteo-
blastic activity and decrease osteoclastic activity [4,6,7], it is
conceivable to speculate that the changes in the circulating
levels of these molecules induced by ZA administration may
reflect an enhanced osteoblastic activity related to bone re-
modelling processes elicited by the drug. These observations
are consistent with other studies which show that ZA stimu-
lates in vitro the proliferation and differentiation of bone tra-
becular osteoblastic cells [35]. Therefore, the Cathepsin K/
Cystatin C system may be regarded as possible, as additional
marker of osteoblastic activity associated with the therapeutic
response of BM patients to bisphosphonate treatments. Never-
theless, their clinical value as specific gauges of skeletal me-
tastasis remains questionable. Further investigations with
a wide number of patients may better define the clinical roleCystatin C
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atin C circulating levels in patients with bone metastases from breast cancer or
135F.M. Tumminello et al. / Biomedicine & Pharmacotherapy 62 (2008) 130e135of these molecules in the diagnosis and clinical management
of patients with cancer related bone disease.
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